Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
BI-9546 was used at 1-10 µM in vitro and cellular assays
and Diabetic peripheral neuropathic pain
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling
The unfolded protein response signals through high-order assembly of Ire1
ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S BI-9546 was used at 1-10ABT 199, CAS No. 1257044 40 8, is a highly potent, selective, and orally bioavailable BCL 2 inhibitor. ABT 199 has picomolar affinity for BCL 2 (Ki < 0. 010 nM) and > 1000 folds selectivity over BCL XL (Ki = 48 nM) and BCL W (Ki = 245 nM). Therefore, ABT 199 is a much improved lead compound over the original ABT 263 (navitoclax) to avoid thrombocytopenia caused by BCL XL inhibition. ABT 199s cell killing effect is selective and mechanism dependent. It
US$ 120.00
US$ 1519.50
US$ 120.00
US$ 2822.00
US$ 100.00
US$ 674.50
US$ 121.00
US$ 120.00